Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma

BACKGROUND: The response rate to sorafenib is limited for unresectable hepatocellular carcinoma (HCC). Little is known about the long-term outcomes of objective responders. The role of second-line therapies on the survival of sorafenib-responders is unclear. We aimed to delineate the long-term outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Kuo-Wei, Lee, Pei-Chang, Chao, Yee, Su, Chien-Wei, Lee, I-Cheng, Lan, Keng-Hsin, Chu, Chi-Jen, Hung, Yi-Ping, Chen, San-Chi, Hou, Ming-Chih, Huang, Yi-Hsiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134461/
https://www.ncbi.nlm.nih.gov/pubmed/35646162
http://dx.doi.org/10.1177/17588359221099401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134461/
https://www.ncbi.nlm.nih.gov/pubmed/35646162
http://dx.doi.org/10.1177/17588359221099401

Ejemplares similares